Iron chelation: a potential therapeutic strategy in oesophageal
BD Keeler1, MJ Brookes2,
British Journal of Pharmacology
Accepted manuscript online: 28 DEC 2012
Manuscript Accepted: 6 DEC 2012

Raised intracellular iron has been identified as a potential
aetiological factor in the development of several epithelial
malignancies including those of the gastrointestinal tract.
The mechanism behind this increase is thought to include disorders of
iron uptake and storage.
Several iron chelators have been identified as potential anti-tumour
agents, with much work undertaken to ascertain the exact mode of
Despite this, there is little known about the role that these drugs
play in the cellular iron metabolism of oesophageal cancer.
Consequently, the present study looks to review the relationship of
two clinically important iron chelating agents, deferoxamine and
deferasirox, on cellular iron uptake and storage in oesophageal
squamous and adenocarcinoma.
This provides important evidence for the debate about the role these
agents have in the clinical management of such tumours.

Keywords:Iron chelation;deferoxamine;deferasirox;anti-tumour
agents;cell cycle

*DOI: 10.1111/bph.12093

© 2012 The Authors. © 2012 The British Pharmacological Society

Who loves ya.

Jesus Was A Vegetarian!

Man Is A Herbivore!